BioPharmSignal logoBioPharmSignal

Biotech News

Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Carisma Therapeutics, Inc. (CARM)Carisma Therapeutics, Inc.Conference / presentation

PHILADELPHIA , Feb. 19, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced that Michael Klichinsky , PharmD, PhD, Co-founder and Chief Scientific Officer, will participate in the H.C.

Related news

MGNXMacroGenics2026-09-09 20:05 EST

MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

FATEFate Therapeutics2026-09-03 11:00 EST

Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference

FATEFate Therapeutics2026-09-09 11:00 EST

Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting

LYELLyell Immunopharma2026-09-14 11:00 EST

Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference

ANABAnaptysBio, Inc.2026-09-01 20:15 EST

Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference

LEGNLegend Biotech Corporation2026-09-01 12:00 EST

Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference

KURAKura Oncology2026-09-01 11:15 EST

Kura Oncology to Participate in Three Investor Conferences in September

ELVNEnliven Therapeutics2026-08-31 22:05 EST

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

CHRSCoherus BioSciences, Inc.2026-08-31 13:30 EST

Coherus to Participate in Upcoming Investor Conferences

CMPXCompass Therapeutics2026-07-17 14:42 EST

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

View all latest news

Carisma Therapeutics, Inc.

Carisma Therapeutics is a cell-therapy company focused on engineered macrophages and cancer immunotherapy. Its story centers on using a novel immune-cell approach to attack tumors.

Recent company news

CARMCarisma Therapeutics, Inc.2025-12-05 16:16 EST

Carisma Announces Delisting from Nasdaq and SEC Deregistration

CARMCarisma Therapeutics, Inc.2025-03-31 20:30 EST

Carisma Therapeutics Provides Corporate Updates

CARMCarisma Therapeutics, Inc.2025-02-19 12:30 EST

Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

CARMCarisma Therapeutics, Inc.2025-02-05 12:30 EST

Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference

CARMCarisma Therapeutics, Inc.2024-12-09 13:30 EST

Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline

Stock data

Close
0.00 USD
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States